Bio News
UK-based GSK said Japan’s Ministry of Health, Labour and Welfare approved the antisense oligonucleotide (ASO) bepirovirsen as a functional cure for chronic hepatitis B. The approval was based on results from the phase 3 B-Well trial, which confirmed a 19% functional cure rate among adults with surface antigen levels of 3000 IU/mL or less. GSK is also pursuing regulatory applications in several regions, including the United States.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
